Crystal has announced the launch of “Boot Walk at Sea,” a summer programme developed in partnership with The University of Texas MD Anderson Cancer Center, extending a long-established charitable initiative from shore to sea aboard Crystal Symphony and Crystal Serenity.
The initiative draws inspiration from UT MD Anderson’s annual Boot Walk to End Cancer, which is scheduled to mark its 11th year in November 2026. Through the onboard programme, guests sailing during the summer season will have the opportunity to participate in promenade walks intended to support cancer research and wellness-focused initiatives.
The series is scheduled to commence aboard Crystal Symphony on May 9th, 2026 and aboard Crystal Serenity on June 2nd, 2026. Timed to coincide with National Walking Month and continuing through National Wellness Month in August, the programme will feature across a selection of Crystal’s wellness-oriented voyages.
Once during each sailing, guests will be invited to take part in a hosted promenade walk along the teak track encircling Deck 7. Participation will remain voluntary, with guests free to complete the circuit at their own pace while contributing optional donations based on the number of laps walked. Funds raised will support the James P. Allison Institute at UT MD Anderson, which advances immunotherapy research building upon the work of Nobel Laureate James P. Allison.
Cristina Levis, chief executive officer of A&K Travel Group, indicated that the collaboration was intended to provide guests with an opportunity to engage in an initiative carrying significance beyond the voyage itself. She noted that the programme reflected Crystal’s broader focus on wellness while also creating purposeful experiences connected to a wider humanitarian effort.
UT MD Anderson’s Boot Walk to End Cancer has grown into a major annual fundraising campaign supporting patient care, education and medical research. According to the institution, the event raised more than US$2 million during its 2025 edition and has generated substantial funding for cancer programmes since its establishment in 2016.